Can I take cabozantinib during radiotherapy? Safety and precautions for combined therapy

Cabozantinib is a multi-target tyrosine kinase inhibitor mainly used to treat advanced renal cancer, liver cancer and certain types of thyroid cancer. It exerts anti-tumor effects by inhibiting tumor angiogenesis and cell proliferation pathways. Radiation therapy is a treatment commonly used for local tumor control, and many patients may receive cabozantinib during radiation therapy. However, whether cabozantinib can be taken concurrently during radiotherapy and the safety of combined therapy are issues worthy of concern.

According to the available clinical data, cabozantinib may increase the risk of some side effects when used in combination with radiotherapy, especially gastrointestinal reactions (such as diarrhea, nausea, etc.) and skin reactions. Cabozantinib itself has certain side effects, especially those related to angiogenesis, such as hypertension, bleeding, and abnormal liver function. Radiotherapy may cause inflammation and damage to local tissues, which may make the patient's immune system more vulnerable and further aggravate side effects. Therefore, when cabozantinib is given along with radiation therapy, doctors usually need to monitor the patient's signs and symptoms closely to make sure the drug does not interact adversely with the radiation therapy.

The safety of combination therapy also depends on the patient's medical condition and the specific area of radiation being treated. For radiotherapy in certain special areas (such as the abdomen, head and neck, etc.), cabozantinib may aggravate the side effects caused by radiotherapy, such as tissue ulceration or bleeding. Therefore, in this case, doctors usually adjust the dose of cabozantinib according to the patient's specific situation, or delay the use of cabozantinib to reduce the occurrence of adverse reactions. In addition, cabozantinib may also have a certain impact on the effect of radiotherapy, especially on the tumor microenvironment and blood supply, so the treatment effects and risks need to be weighed.

Overall, the use of cabozantinib during radiotherapy is feasible but requires caution. The safety of combination therapy depends on the patient's individualized assessment. Doctors need to consider factors such as the patient's health status, radiotherapy site, and drug dosage. During the treatment process, patients should undergo regular physical examinations, monitor the occurrence of side effects, and communicate with their doctors in a timely manner to ensure the safety and effectiveness of the treatment plan. In most cases, the combined use of cabozantinib and radiation therapy can be performed under the guidance of a professional physician to improve treatment effectiveness and reduce potential risks.

Reference:https://en.wikipedia.org/wiki/Cabozantinib